Skip to content

Study · Randomized controlled trial · n = 17 · 2016

2 results

Intranasal oxytocin dampens cue-elicited cigarette craving in daily smokers: a pilot study.

Miller MA, Bershad A, King AC, Lee R, de Wit H

Behavioural pharmacology1 Dec 2016Cited by 29 (Europe PMC)

PMID27661192 (opens in a new tab)PMCIDPMC5089916 (opens in a new tab)DOI10.1097/fbp.0000000000000260 (opens in a new tab)PepBankPUB-27661192
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In abstinent daily smokers, intranasal oxytocin did not reduce spontaneous cigarette craving after the first spray versus placebo.

    In plain wordsIn smokers who had not smoked for 12 hours, oxytocin did not reduce ordinary craving compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSpontaneous cigarette craving after first spray
    Study

    n = 17

    Comparator
    Placebo (saline nasal spray)
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    20 IU, two doses at 1-h intervals · intranasalAs given in this study (human).

    Source sentences

    Summary
    OT did not reduce levels of spontaneous craving after the first spray
    2 context sentences
    Summary · context
    In this within-subject, placebo-controlled pilot study, smokers (N=17) abstained from smoking for 12 h before attending two sessions randomized to intranasal OT or placebo (i.e. saline nasal spray).
    Summary · context
    On each session, participants received two doses of OT (20 IU) or placebo at 1-h intervals, and rated craving before and after each dose.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In abstinent daily smokers, intranasal oxytocin significantly dampened cue-induced smoking craving versus placebo.

    In plain wordsIn smokers who had not smoked for 12 hours, oxytocin reduced craving triggered by smoking cues, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseCue-induced cigarette craving
    Study

    n = 17

    Comparator
    Placebo (saline nasal spray)
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    20 IU, two doses at 1-h intervals · intranasalAs given in this study (human).

    Source sentences

    Summary
    but significantly dampened cue-induced smoking craving.
    2 context sentences
    Summary · context
    In this within-subject, placebo-controlled pilot study, smokers (N=17) abstained from smoking for 12 h before attending two sessions randomized to intranasal OT or placebo (i.e. saline nasal spray).
    Summary · context
    On each session, participants received two doses of OT (20 IU) or placebo at 1-h intervals, and rated craving before and after each dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.